SANOCHEMIA Pharmazeutika AG: Grant of patent for Vidon® Photodynamic Therapy of Bladder Cancer in the USA

Wien (pta008/23.10.2018/09:14 UTC+2) Vienna, October 23, 2018 - Sanochemia Pharmazeutika AG, Vienna (ISIN AT0000776307 ISIN DE000A1G7JQ9),announces that the United States Patent and Trademark Office has issued "Notice of Allowance" for Vidon® in Photodynamic Therapy (PDT) of bladder cancer.

Vidon® (PVP-Hypericin) is one of Sanochemia`s promising pipeline products and is being developed as a game changing technology in the management of bladder cancer. The patent covers the method for therapy of bladder cancer with Sanochemia's developed PVP-Hypericin formulation. The U.S. patent will protect Vidon® until 2035.

"The Notice of Allowance for the US application of Vidon® for PDT is an important milestone to secure the long-term value of Vidon® for Sanochemia", said Dr. Christina Abrahamsberg, CSO of Sanochemia Pharmazeutika AG.
-------------------------------------------------------------------------------------------------------
Bladder cancer is the most common malignancy of the urinary tract. Approximately 75% of initially diagnosed bladder cancers are non-muscle invasive tumors, which means that the tumor is restricted to the mucosa. In 30-80% of the patients, recurrences occur, requiring repeated surgeries. About 45% of bladder cancers will progresses to a muscle-invasive bladder carcinoma.

Early detection, timely and appropriate treatment are therefore essential factors for improving the prognosis of urinary bladder carcinoma patients.

Photodynamic therapy (PDT) is a method of treating bladder tumors with a photosensitizer and light. The method is based on the selective accumulation of the photosensitizer in malignant cells and the irradiation of the tumor tissue with light of a specific wavelength. Subsequently, photochemical processes generate toxic substances that specifically damage the tumor.
Vidon® is developed by Sanochemia Pharmazeutika AG as a diagnostic and therapeutic option for patients with non-muscle invasive bladder cancer.

(end)

Emitter:	SANOCHEMIA Pharmazeutika AG Boltzmanngasse 11 1090 Wien Austria
Contact Person:	Bettina Zuccato
Phone:	+43 1 3191456-336
E-Mail:	b.zuccato@sanochemia.at
Website:	www.sanochemia.at
ISIN(s):	AT0000776307 (Share)
Stock Exchange(s):	Free Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Munich, Stuttgart; Vienna Stock Exchange (mid Market)